First-line immunotherapy in Chinese adults with newly diagnosed multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort enrolling approximately 500 adults with newly diagnosed multiple myeloma who plan to receive first-line immunotherapy at participating Chinese centers. Investigators will record baseline disease features, specific treatment regimens (anti-CD38 monoclonal antibodies, proteasome inhibitors, IMiDs, and combinations), and clinical outcomes during one year of follow-up. Data collection will focus on real-world treatment patterns, response rates, and short-term safety, with plans for longer-term follow-up to capture survival and causes of death. The goal is to generate real-world evidence to inform individualized treatment choices in Chinese NDMM patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed multiple myeloma (NDMM)
* Plan to receive first-line immunotherapy at the respective research center
* First-line immunotherapy includes proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), or anti-CD38 monoclonal antibodies, used alone or in combination with each other or with other treatments
* Age ≥ 18 years
* Ability to understand the purpose of the study and follow-up process
* Willingness to provide signed and dated written informed consent

Exclusion Criteria:

\- Patients who did not receive any follow-up after initial diagnosis

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Prof. LU, MD — Peking University People's Hospital
• Study coordinator: Prof. LIU, MD
• Email: pkuphliuyang@bjmu.edu.cn
• Phone: +8613716926210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fewer-doses daratumumab added to VRd for newly diagnosed multiple myeloma

  This study tests whether a less-frequent daratumumab dosing plan added to VRd can help patients with newly diagnosed multiple myeloma achieve more MRD negativity.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07891923

• AZD0120 consolidation vs ASCT in transplant-eligible newly diagnosed multiple myeloma

  This study tests whether AZD0120 given as consolidation can work as well as or better than traditional autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma.

  Recruiting at 2 sites Phase 3 AstraZeneca · Gilbert, Arizona and 113 other locations · NCT07735637

• First-line RN1201 CAR-T for newly diagnosed multiple myeloma

  This early, small study tests a once-dosed, donor-derived CAR-T therapy (RN1201) in adults with newly diagnosed multiple myeloma to see if it is safe and if patients respond.

  Recruiting Phase 1 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07652138

• Combining PET scans and bone marrow genetic testing to better predict relapse in newly diagnosed multiple myeloma patients

  This project tries combining FDG PET/LDCT imaging and whole-exome sequencing of bone marrow to detect minimal residual disease and better predict progression for transplant-eligible newly diagnosed multiple myeloma patients.

  Recruiting at 4 sites Universiteit Antwerpen · Antwerp, Antwerpen and 3 other locations · NCT07087964

• Using 18F-fluciclovine PET/CT to detect multiple myeloma

  This study is testing a new imaging method using a special tracer to see if it can better detect multiple myeloma in adults compared to the current method.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06103838

• MRD‑guided BCMA CAR-T with optional GPRC5D/CD3 BiTE consolidation for transplant‑ineligible newly diagnosed multiple myeloma

  This trial will try MRD‑guided immunotherapy using BCMA CAR‑T for adults newly diagnosed with multiple myeloma who cannot have a transplant, adding a GPRC5D/CD3 bispecific antibody for those at very high risk.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07106736

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.